Calamos Advisors
AEON icon

Calamos Advisors’s AEON Biopharma AEON Stock Holding History

Calamos Advisors’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,472
Closed -$2.46M – 1235
2022
Q3 		$2.46M Buy
+3,472
New +$2.46M 0.01% 834

Other funds holding AEON

ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Calamos Advisors's AEON Position: Q4 2022 in Review

Calamos Advisors sold out of AEON Biopharma (AEON) in Q4 2022, closing a stake of 3,472 shares — an estimated $2.46M sold.

Calamos Advisors first reported a position in AEON in Q3 2022 and held it in 1 quarter. The position peaked at $2.46M in Q3 2022. 85 funds tracked by Wall St. Rank hold AEON as of Q4 2022.

  • Calamos Advisors reported no remaining AEON Biopharma position as of Q4 2022 after selling out during the quarter.
  • Calamos Advisors sold 3,472 AEON Biopharma shares in Q4 2022, an estimated $2.46M.
  • Calamos Advisors first reported a position in AEON Biopharma in Q3 2022 and held it in 1 quarter.
  • Calamos Advisors's AEON Biopharma position peaked at $2.46M in Q3 2022.
  • 85 funds tracked by Wall St. Rank held AEON Biopharma as of Q4 2022.

Based on Calamos Advisors's 13F filing for Q4 2022, filed 26 Jan 2023.